We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Europe Phasing Out of Extraordinary COVID-19 “Regulatory Flexibility”
Europe Phasing Out of Extraordinary COVID-19 “Regulatory Flexibility”
The European Medicines Agency (EMA), the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the “extraordinary regulatory flexibilities” that were put in place during the COVID-19 pandemic to ease potential medicine shortages.